Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
Z

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are More Effective and Tolerated, Interferon Alfa Not Recommended for Cutaneous Disease, & What Therapy in BRAF Mutant Disease

By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
25 views
December 4, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Skin
14:32
Xth Eurasian Hematology-Oncology Congress

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Feat. Z. Turna
06:35
Xth Eurasian Hematology-Oncology Congress

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Feat. Z. Turna
21:19
Xth Eurasian Hematology-Oncology Congress

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Feat. S. Seber
05:25
Xth Eurasian Hematology-Oncology Congress

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Feat. D. Erdem
15:44
Xth Eurasian Hematology-Oncology Congress

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Feat. D. Erdem